Navigation Links
Two Phase III clinical trials on corifollitropin alfa (Org 36286),reach randomization target

OSS, the Netherlands, June 27, 2007-Organon, the human healthcare business unit of Akzo Nobel, announced today that two out of three Phase III clinical trials with corifollitropin alfa (Org 36286), a new long-acting fertility hormone, have reached their randomization target.

Corifollitropin alfa is a new recombinant fertility hormone. It is the first of a new class of gonadotropins (a sustained follicular stimulant or SFS) of which, due to its long half-life, one single injection may replace the first 7 injections with conventional gonadotropins during a fertility treatment cycle.

The objective of the ENGAGE trial, the largest double-blind fertility trial ever performed, is to demonstrate clinical efficacy and safety of corifollitropin alfa 150 µg in a double-blind comparison with Organon’s Puregon®, one of the most commonly used preparations to treat infertile patients. The recruitment goal of the ENGAGE trial was to include a total of 1400 patients from 34 fertility clinics in Europe, USA and Canada and was started in July, 2006. The study reached its randomization target on June 10, 2007.

A second trial, the ENSURE trial, is an efficacy and safety trial with corifollitropin alfa 100 µg designed specifically for women who weigh less than 60 kg (133 lbs). This double-blind study comparing corifollitropin alfa with Puregon® was started in January 2007 in 19 clinical trial centers in Europe and Asia with a recruitment goal of 330 patients by June 30, 2007. All 330 subjects have now been randomized.

David Nicholson, executive vice-president Research and Development at Organon commented: “The enthusiasm and dedication of investigators and staff involved in these trials was decisive in reaching our recruitment targets.”

A third Phase III trial in the LIFE program (the TRUST trial) focuses on safety of repeated treatments with corifollit ropin alfa, and is expected to complete recruitment on target by mid-August 2007.

About corifollitropin alfa
• Corifollitropin alfa is a new biological entity (NBE) and is being developed for controlled ovarian stimulation to induce the development of multiple follicles in patients participating in an assisted reproductive technology program.
• Corifollitropin alfa is the first compound in a new class of long-acting fertility hormones called ‘Sustained Follicle Stimulants’ (SFS). The primary advantage of an SFS over current gonadotropins is the longer duration of action which allows a treatment regimen replacing 7 daily injections of current gonadotropins with one injection of corifollitropin alfa.
• The LIFE program is Organon’s clinical development program for corifollitropin alfa for the therapeutic indication of controlled ovarian stimulation. The most important trials in this program are studies with the names ENGAGE (phase III efficacy and safety study with corifollitropin alfa 150 mcg), ENSURE (phase III efficacy and safety study in women =60 kg with corifollitropin alfa 100 mcg) and TRUST (phase III safety study on repeated treatment).


For media inquiries
Elina Daamen

N.V. Organon (Media Relations)
Visiting address: Molenstraat 110
5342 CC Oss
The Netherlands
Mailing address:

Elina Daamen, media relations

NV Organon

Tel: +31-412-663685

Fax: +31 (0) 412 662568
Email address: elina.daamen@organon.com


About Organon
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage its position as a leading biopharmaceutical company in each of its core therapeutic fields: fertility, gynecology and selected areas of anesthesia. It has extensive expertise in neuroscience and a rich and focused R&D program. Research areas also include immunology and specific areas of oncology. Organon products are distributed in over 100 countries worldwide, of which more than 50 have an Organon subsidiary. Organon is the human healthcare business unit of Akzo Nobel.
'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)...  Life Flight Network and PeaceHealth Oregon Network announced they ... and operational efficiency for patients at hospitals in ... Cottage Grove , and Florence, Oregon ... Flight Network work collaboratively to move patients who require the ... time sensitive emergency exists. ...
(Date:7/31/2017)... Pharmacy, Inc. (NYSE: DPLO), has been named one of the ... Crain,s Detroit Business . The annual Crain,s Fast ... growth. This year,s edition measures growth from 2013 to 2016. ... list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being named ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve made ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
Breaking Medicine Technology:
(Date:8/21/2017)... ... August 21, 2017 , ... Duncan Insurance Agency debuts the ... of Michigan. The new initiative fundraises for the Kalamazoo Humane Society (KHS), which ... animal protection and welfare by addressing the root causes of pet overpopulation. As ...
(Date:8/21/2017)... ... August 21, 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, ... announced his candidacy for the 52nd Congressional District currently held by Representative Scott Peters. ... to this country at age eleven after suffering homelessness and hardship in a distant ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA ... Management System has assisted multiple clients in successfully passing audits such as ... Control Level 2 (AICPA SOC Level 2), and State Data Use Agreement Audits. ...
(Date:8/19/2017)... (PRWEB) , ... August 18, 2017 , ... Western University ... health and education to launch the University’s new Center for Innovation on Wednesday, September ... Health Education Center Lecture Hall 1, followed by a technology exhibition from 1 to ...
(Date:8/19/2017)... ... August 19, 2017 , ... Curl Keeper® is excited ... The Curl Leaders, Editors’ Choice 2017 Award for the second year in a row. ... stylists and curlies alike was voted Best Moisturizer for Type 2 Wavies and Best ...
Breaking Medicine News(10 mins):